Alnylam Adds Vutrisiran as Twice Yearly Injection to HELIOS Extension Trial

Alnylam Adds Vutrisiran as Twice Yearly Injection to HELIOS Extension Trial

294387

Alnylam Adds Vutrisiran as Twice Yearly Injection to HELIOS Extension Trial

Alnylam Pharmaceuticals has initiated testing of a twice a year dosing regimen for vutrisiran, its investigational RNA-targeted therapy for familial amyloid polyneuropathy (FAP) and other forms of ATTR amyloidosis. The new dosing regime is being added to the open-label extension phase of the ongoing Phase 3 HELIOS-A trial (NCT03759379) that is now underway for vutrisiran. Findings from this extension are expected by 2022 and, if positive, will be used to support the submission of a supplemental new drug application requesting U.S. Food…

You must be logged in to read/download the full post.